The overarching objective of this DDRCC is to foster and facilitate research in inflammatory bowel diseases (IBD) and related inflammatory diseases of the bowel. This theme has defined our GI program for 75 years, ever since Dr. Joseph B. Kirsner, the founder of modern gastroenterology at the University of Chicago, put forward the hypothesis that inflammatory bowel diseases are caused by combination of genetic, immunological, and microbial factors. We now know this is indeed the case, but recognize that other factors associated with recent changes in environment, lifestyle, and diet, are contributing to the increased prevalence and incidence of these diseases. The DDRCC has been the foundation of IBD research at the University of Chicago allowing us to build a highly collaborative, multidisciplinary team, a fully integrated translational research infrastructure, an state-of-the-art core facilities and services. In addition, the DDRCC has partnered with two University of Chicago affiliates, Argonne National Laboratory (ANL) and the Marine Biological Laboratory (MBL) at Woods Hole, to attract new investigators to the field and leverage their resources, talent, and facilities for the investigation of inflammatory diseases of the bowel. The central hypothesis of the collective group is that IBD and related inflammatory diseases of the bowel arise from a confluence of host, microbial, immunological, and environmental factors. The program is now in its 24th year, and, despite being a highly focused research program, the research base has steadily increased to 51 full and 16 associate member investigators with a total annual direct cost funding for digestive diseases of $14.8 million, of which ~$5.7 million comes from NIDDK (21% increase from 2009). The program has 4 major interrelated research themes that focus on the etiopathogenesis of IBD: (1) host immune/tissue responses, (2) the gut microbiome, (3) host genetics and gene function, and (4) environmental modifiers. The 4 DDRCC cores embracing these themes have continuously evolved to meet the needs of investigators and to anticipate new trends and technologies in biomedical research. The DDRCC has received tremendous institutional support as 1 of 5 priority areas designated for development by the Division of Biological Sciences. The DDRCC has successfully supported new investigators, but also drawn in talented scientists outside of the field of digestive diseases (15 now full members since 2010). Over the past two funding cycles, the P&F program has resulted in over $25M in extramural funds, or a 25 to 1 return-on-investment. Over the past funding cycle, 56% of the 306 publications acknowledging the DDRCC for its support were coauthored by two or more DDRCC members, indicating a high level of collaborative science. The number of high impact papers (Impact factor>20) published by DDRCC members has nearly doubled compared to the previous funding cycle. Thus, the DDRCC has successful met its goals of advancing the science and translation of discovery in inflammatory diseases of the bowel. The DDRCC as a whole is greater than the sum of its parts. It provides strategic vision, cutting-edge, high quality, and cost-effective services and resources, and gives opportunity to current and next generation scientists to flourish in a highly collaborative and productive environment.
The overarching objective of this DDRCC is to foster and facilitate research in inflammatory bowel diseases (IBD) and related inflammatory diseases of the bowel. The central hypothesis of the collective group is that IBD and related inflammatory diseases of the bowel arise from a confluence of host, microbial, immunological, and environmental factors. The DDRCC has successful met its goals of advancing the science and translation of discovery in inflammatory diseases of the bowel. The DDRCC as a whole is greater than the sum of its parts. It provides strategic vision, cutting-edge, high quality, and cot-effective services and resources, and gives opportunity to current and next generation scientists to flourish in a highly collaborative and productive environment.
|Lu, Lei; Claud, Erika C (2018) Intrauterine Inflammation, Epigenetics, and Microbiome Influences on Preterm Infant Health. Curr Pathobiol Rep 6:15-21|
|Lu, Jing; Synowiec, Sylvia; Lu, Lei et al. (2018) Microbiota influence the development of the brain and behaviors in C57BL/6J mice. PLoS One 13:e0201829|
|Shiloh, Ruth; Gilad, Yuval; Ber, Yaara et al. (2018) Non-canonical activation of DAPK2 by AMPK constitutes a new pathway linking metabolic stress to autophagy. Nat Commun 9:1759|
|Wang, Haitao; Cheng, Minying; Dsouza, Melissa et al. (2018) Soil Bacterial Diversity Is Associated with Human Population Density in Urban Greenspaces. Environ Sci Technol 52:5115-5124|
|Khambu, Bilon; Huda, Nazmul; Chen, Xiaoyun et al. (2018) HMGB1 promotes ductular reaction and tumorigenesis in autophagy-deficient livers. J Clin Invest 128:2419-2435|
|Cason, Cori A; Dolan, Kyle T; Sharma, Gaurav et al. (2018) Plasma microbiome-modulated indole- and phenyl-derived metabolites associate with advanced atherosclerosis and postoperative outcomes. J Vasc Surg 68:1552-1562.e7|
|Christensen, B; Micic, D; Gibson, P R et al. (2018) Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther 47:753-762|
|Peñalver Bernabé, Beatriz; Cralle, Lauren; Gilbert, Jack A (2018) Systems biology of the human microbiome. Curr Opin Biotechnol 51:146-153|
|Amin, Ruhul; Asplin, John; Jung, Daniel et al. (2018) Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria. Kidney Int 93:1098-1107|
|Lu, Jing; Lu, Lei; Yu, Yueyue et al. (2018) Effects of Intestinal Microbiota on Brain Development in Humanized Gnotobiotic Mice. Sci Rep 8:5443|
Showing the most recent 10 out of 697 publications